SS-31 (Elamipretide): The Mitochondrial Peptide Evidence Reviewed (2026)

Last updated: June 2026

Medical disclaimer: This article is for informational purposes only and is not medical advice. SS-31/elamipretide is an investigational drug for nearly every use people ask about, and it is FDA-approved only for the ultra-rare genetic disorder Barth syndrome (branded FORZINITY, approved September 2025) as of 2026. It is not approved for heart failure, aging, athletic recovery, or general "mitochondrial support." Do not start, stop, or change any treatment based on what you read here. Consult a licensed clinician.

SS-31 is one of the few "research peptides" sold online that has a long, real clinical record. Most do not. That makes the evidence worth reading closely.

This review walks through what SS-31 is, what the lab and animal data show, and what happened when it was tested in actual humans. The short version: real science, mostly disappointing trials, one narrow approval.

What is SS-31 (elamipretide) and how does it work?

SS-31 is a synthetic four-amino-acid peptide that concentrates inside mitochondria and binds cardiolipin, a fat that helps shape the inner mitochondrial membrane. Its chemical sequence is D-Arg-2',6'-dimethyltyrosine-Lys-Phe-amide. The drug name is elamipretide; older names include MTP-131 and Bendavia.

The peptide was designed in the lab of Hazel Szeto and Peter Schiller in the early 2000s. The "SS" comes from their two last names. It crosses cell membranes without burning energy and piles up in the inner mitochondrial membrane at concentrations roughly 1,000 to 5,000 times higher than outside (PMC7247319).

Cardiolipin is the target. It sits in the inner membrane and helps organize the electron transport chain, the assembly line that makes ATP. When cardiolipin gets oxidized or disorganized, electrons leak, energy output drops, and damaging reactive oxygen species build up.

SS-31 binds cardiolipin and is thought to stabilize the membrane structure, protect the electron transport chain, and cut ROS leakage (PMC7247319). The idea is simple. Steady the membrane, and the power plant runs cleaner.

That mechanism is why people lump SS-31 in with "anti-aging" peptides. Mitochondrial decline tracks with aging. But a clean mechanism on a slide is not the same as a benefit you can feel, and the human trials make that gap clear.

What does the preclinical evidence show?

In animals and isolated tissue, SS-31 has repeatedly protected mitochondria under stress, especially in heart attack-style injury, kidney damage, and aging muscle. The preclinical record is broad and genuinely strong. That is part of why the drug got so much investment.

The most-cited early work is in heart ischemia-reperfusion: the damage that happens when blood flow returns to starved tissue. In rodent heart-attack models, SS-31 given before or at reperfusion shrank infarct size, kept mitochondrial membrane potential up, and improved how the heart recovered.

Kidney research follows the same pattern. SS-31 reduced injury and preserved mitochondrial function in models of acute and chronic kidney disease (PMC9192202). The proposed reason is the same cardiolipin-stabilizing effect protecting energy-hungry tubule cells.

Aging skeletal muscle is another active area. In old mice, SS-31 has improved muscle energetics and fatigue resistance in several reports, which fueled the human muscle and exercise studies. Some of this work showed improved mitochondrial coupling and faster recovery of energy stores after exercise, which is the kind of result that gets quoted in marketing copy.

A 2025 review pulled the mechanism literature together and described how elamipretide acts on the inner membrane to restore cristae structure and respiratory efficiency across these tissue types (ScienceDirect 2025).

There is also direct work in Barth syndrome models, the disease where SS-31 eventually won approval. In a mouse model, SS-31 improved cardiac mitochondrial shape and restored defective mitophagy (Nature Sci Rep 2024).

Here is the honest caveat. Strong animal data is normal in drug development. Most compounds that look great in mice still fail in people. SS-31 is, unfortunately, a textbook example of that drop-off.

What human trials has elamipretide been in?

Elamipretide has run through more than a dozen human trials across heart failure, mitochondrial myopathy, dry AMD, and Barth syndrome, and most of the large ones missed their primary endpoints. This is the heart of the evidence, so be skeptical of any vendor that only quotes the mouse studies.

Start with heart failure. The PROGRESS-HF Phase 2 trial (NCT02788747) randomized 71 patients with reduced-ejection-fraction heart failure to placebo, 4 mg, or 40 mg of elamipretide daily for 28 days. Change in left ventricular end-systolic volume was no different from placebo. The drug was well tolerated but did nothing measurable to heart function (Butler et al., JACC Heart Failure 2020; PMID 32068002).

Primary mitochondrial myopathy was the most ambitious test. MMPOWER-3 (NCT03323749), a Phase 3 trial, randomized 218 genetically confirmed patients to 40 mg/day subcutaneous elamipretide or placebo for 24 weeks. It failed both primary endpoints: the 6-minute walk distance and a fatigue score did not beat placebo (Neurology 2024; PMC10382259).

A later post-hoc analysis of MMPOWER-3 suggested a possible benefit in one genetic subgroup (mtDNA replisome disorders), but post-hoc signals are hypotheses, not proof (Orphanet J Rare Dis 2024).

Eye disease was next. ReCLAIM-2 (NCT03891875) was a Phase 2 trial in dry age-related macular degeneration with geographic atrophy, using 40 mg daily subcutaneously for 48 weeks. It did not meet its primary endpoints for visual acuity or atrophy growth, though some secondary signals kept the program alive into Phase 3 (Ophthalmology Science 2024; PMC11599447).

The one success was the smallest study. TAZPOWER (NCT03098797) enrolled just 12 Barth syndrome patients in a crossover design. The randomized phase showed no benefit, but the open-label extension showed large gains in knee-extensor strength over many months, and that is what the approval rested on (FDA, 2025).

See the <a href="#study-table">study table below</a> for the side-by-side results.

Is SS-31 approved or available in 2026?

As of 2026, elamipretide is FDA-approved only for Barth syndrome, branded FORZINITY, and only for patients weighing at least 30 kg; it is not approved for any other use. The FDA granted accelerated approval on September 19, 2025, making it the first cardiolipin-targeted mitochondrial therapy ever cleared (FDA, 2025).

The road there was rocky. An FDA advisory committee split 10-6 in favor of effectiveness in October 2024. The agency then issued a Complete Response Letter before the program was resubmitted for accelerated approval based on muscle strength. A confirmatory trial is required as a condition of that approval.

Accelerated approval matters here. It means the FDA accepted a surrogate measure (knee-extensor strength) as "reasonably likely" to predict benefit. The drug could still be pulled if the confirmatory trial fails.

So what about the "SS-31" sold by research-chemical vendors? That is a separate world. Those vials are sold "for research use only," not as the approved Barth syndrome drug, and they sit outside the FDA-approved supply chain entirely.

Buying research-grade peptides online carries real quality, purity, and legal questions. We cover those in our peptide legality guide for 2026 and our breakdown of compounded peptides versus research chemicals.

What are the reported dosing forms?

In published human trials, elamipretide was given as a once-daily subcutaneous injection, most commonly at 40 mg. This is observational reporting from the trial record, not a protocol for personal use.

The 40 mg/day subcutaneous dose appears across MMPOWER-3, ReCLAIM-2, and TAZPOWER. PROGRESS-HF tested 4 mg and 40 mg daily. Early heart studies also used intravenous infusions.

Research-chemical vendors sell SS-31 as a lyophilized powder for reconstitution, usually in 10 mg to 50 mg vials. There are no validated, evidence-based dosing protocols for unapproved personal use, and the trial doses were chosen for specific diseases under medical supervision.

We do not provide dosing guidance for unapproved use. If a vendor publishes a confident "protocol," treat that as marketing, not medicine.

What are the risks and unknowns?

Across trials, elamipretide was generally well tolerated, with injection-site reactions the most common complaint, but long-term safety in healthy people is essentially unstudied. Most reported adverse events were mild to moderate, and the safety record is one of the few consistently positive parts of the program.

That said, the unknowns are large. The drug was studied in sick patients for months, not in healthy adults for years. We have little data on long-term use for aging or performance, which is exactly how the gray market sells it.

Quality is a second risk. Research-chemical SS-31 has no guaranteed purity, sterility, or dose accuracy. Independent testing of peptide vendors routinely finds underdosing and contamination, which we track in our vendor testing roundup.

There is also a regulatory unknown. The Barth syndrome approval was accelerated and rests on a surrogate marker, so the confirmatory trial still has to deliver. If it does not, the approval can be withdrawn, which would leave the drug with zero confirmed indications.

The biggest unknown is whether the mechanism even helps people who are not sick. A drug that stabilizes failing mitochondria in disease may do little in a healthy 35-year-old. The trial record, where benefits were hard to find even in patients, should temper expectations.

The bottom line

SS-31/elamipretide has the rarest thing in the peptide world: a deep, real clinical record. The mechanism is well-described, the animal data is strong, and the safety profile looks clean.

But the large human trials in heart failure, mitochondrial myopathy, and dry AMD all missed their primary endpoints. The single approval is for Barth syndrome, an ultra-rare disease, in a 12-person trial that only worked in its open-label phase.

For the uses people actually buy SS-31 for online (energy, anti-aging, recovery), there is no human evidence of benefit and no approved product. The honest read is a fascinating molecule with a sobering trial history.

Related Reading

• Epithalon and the pineal gland: a research review
• Peptide legality guide 2026
• Best peptide vendors 2026: third-party tested
• Growth hormone peptides: sermorelin, ipamorelin, CJC-1295

<a id="study-table"></a>

SS-31 / elamipretide trial evidence at a glance

Trial / Study (year)	Population	Sample (n)	Primary endpoint result
Szeto-Schiller mechanism work (PMC7247319)	Lipid bilayers / cell models	N/A (preclinical)	Confirmed cardiolipin binding, membrane stabilization
SS-31 in kidney disease (PMC9192202)	Rodent kidney injury	Preclinical	Reduced injury, preserved mitochondrial function
PROGRESS-HF, Butler et al. 2020 (NCT02788747)	HFrEF (LVEF ≤40%)	71	Negative: no change in LV end-systolic volume vs placebo
MMPOWER-3, 2024 (NCT03323749)	Primary mitochondrial myopathy	218	Failed: no benefit on 6-min walk or fatigue score
ReCLAIM-2, 2024 (NCT03891875)	Dry AMD with geographic atrophy	~176	Missed primary endpoints (acuity, atrophy growth)
TAZPOWER, 2025 (NCT03098797)	Barth syndrome	12	Negative in RCT phase; strength gains in open-label extension (basis of approval)

Frequently asked questions

Is SS-31 the same thing as elamipretide? Yes. SS-31, elamipretide, MTP-131, and Bendavia are all names for the same tetrapeptide. The FDA-approved brand for Barth syndrome is FORZINITY.

Is SS-31 FDA-approved? Only for one disease. Elamipretide was approved in September 2025 for Barth syndrome under accelerated approval. It is not approved for heart failure, aging, recovery, or general mitochondrial support.

Does SS-31 work for anti-aging or energy? There is no human trial evidence that SS-31 improves energy, longevity, or performance in healthy people. Its mechanism targets failing mitochondria in disease, and even those trials mostly missed their goals.

How is elamipretide given in studies? In published trials it was given as a once-daily subcutaneous injection, usually 40 mg. This is a description of the trial record, not a recommendation for personal use.

Is research-grade SS-31 from peptide websites safe? Those products are sold "for research use only," are not the approved drug, and have no guaranteed purity or sterility. The legal and quality risks are real and covered in our legality guide.

Researched and drafted by Theo Park, an AI editorial persona at Peptide Front, against published sources. Reviewed by our editorial team.